loading
Schlusskurs vom Vortag:
$23.60
Offen:
$22.04
24-Stunden-Volumen:
5.02M
Relative Volume:
1.08
Marktkapitalisierung:
$2.76B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-25.74
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
+11.25%
1M Leistung:
-19.75%
6M Leistung:
-62.95%
1J Leistung:
-63.98%
1-Tages-Spanne:
Value
$21.23
$24.12
1-Wochen-Bereich:
Value
$21.21
$27.09
52-Wochen-Spanne:
Value
$18.92
$81.86

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Firmenname
Viking Therapeutics Inc
Name
Telefon
858-704-4660
Name
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Mitarbeiter
36
Name
Twitter
@viking_vktx
Name
Nächster Verdiensttermin
2024-10-23
Name
Neueste SEC-Einreichungen
Name
VKTX's Discussions on Twitter

Vergleichen Sie VKTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VKTX
Viking Therapeutics Inc
23.94 2.76B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet Goldman Neutral
2025-02-13 Eingeleitet Scotiabank Sector Outperform
2025-02-07 Eingeleitet Citigroup Neutral
2024-12-02 Eingeleitet Piper Sandler Overweight
2024-11-22 Eingeleitet B. Riley Securities Buy
2024-11-04 Bestätigt H.C. Wainwright Buy
2024-09-11 Eingeleitet JP Morgan Overweight
2024-06-27 Eingeleitet Morgan Stanley Overweight
2024-05-16 Hochstufung Raymond James Outperform → Strong Buy
2024-03-26 Bestätigt Oppenheimer Outperform
2024-03-07 Eingeleitet Jefferies Buy
2024-02-28 Bestätigt Oppenheimer Outperform
2023-05-31 Fortgesetzt ROTH MKM Buy
2023-03-28 Bestätigt Maxim Group Buy
2023-03-17 Eingeleitet Stifel Buy
2021-07-29 Fortgesetzt BTIG Research Buy
2021-05-25 Herabstufung Raymond James Strong Buy → Outperform
2020-06-05 Eingeleitet BMO Capital Markets Outperform
2020-05-05 Eingeleitet Chardan Capital Markets Buy
2020-05-01 Eingeleitet BTIG Research Buy
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-25 Eingeleitet Stifel Buy
2019-03-29 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-03-14 Bestätigt Maxim Group Buy
2019-02-22 Eingeleitet SVB Leerink Mkt Perform
2018-12-12 Eingeleitet B. Riley FBR Buy
2018-11-19 Hochstufung Raymond James Outperform → Strong Buy
2018-09-18 Bestätigt H.C. Wainwright Buy
2018-09-18 Bestätigt Maxim Group Buy
2018-09-18 Bestätigt Raymond James Outperform
2018-07-20 Eingeleitet SunTrust Buy
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-01 Bestätigt Laidlaw Buy
2018-05-31 Bestätigt Maxim Group Buy
2018-03-26 Fortgesetzt H.C. Wainwright Buy
2017-11-28 Bestätigt Maxim Group Buy
2017-11-21 Eingeleitet ROTH Capital Buy
Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

pulisher
Apr 18, 2025

Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics - Yahoo Finance

Apr 18, 2025
pulisher
Apr 17, 2025

Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo

Apr 17, 2025
pulisher
Apr 17, 2025

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide - Yahoo Finance

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics (VKTX) Gains Attention with Promising Diabetes Treatment | LLY Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

2 Stocks Down by 25% or More This Year to Buy and Hold - Yahoo Finance

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics: A Lot More Compelling After The MeltdownInitiating Cautious Buy (Rating Upgrade) - Seeking Alpha

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics (VKTX) to Announce Q1 2025 Financial Results - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics Inc (VKTX) Stock Price, Trades & News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics (VKTX) Shares Decline Following Eli Lilly's Phase 3 Results | LLY Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Viking Therapeutics slips after Eli Lilly reports orforglipron trial results - TipRanks

Apr 17, 2025
pulisher
Apr 16, 2025

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Quantisnow

Apr 16, 2025
pulisher
Apr 16, 2025

Viking Therapeutics to Report Financial Results for First Quarte - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Viking Therapeutics Sets Q1 Earnings Date: Key Updates Expected on Metabolic Drug Pipeline - Stock Titan

Apr 16, 2025
pulisher
Apr 16, 2025

Viking Therapeutics Stock Pops But Struggles to Hold Gains - MarketBeat

Apr 16, 2025
pulisher
Apr 16, 2025

Viking Therapeutics Stock Pops But Struggles To Hold Gains - Barchart.com

Apr 16, 2025
pulisher
Apr 16, 2025

Viking Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VKTX - Benzinga

Apr 16, 2025
pulisher
Apr 15, 2025

Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Zacks Investment Research

Apr 15, 2025
pulisher
Apr 15, 2025

Viking Therapeutics (VKTX) Surges as Pfizer Halts Obesity Drug - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4) - Quantisnow

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg.com

Apr 14, 2025
pulisher
Apr 14, 2025

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Globe and Mail

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer's $130B Weight-Loss Dream Just Collapsed - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug - Schaeffer's Investment Research

Apr 14, 2025
pulisher
Apr 14, 2025

Viking Therapeutics shares surge on Pfizer’s drug discontinuation By Investing.com - Investing.com India

Apr 14, 2025
pulisher
Apr 14, 2025

Viking Therapeutics shares surge on Pfizer’s drug discontinuation - Investing.com

Apr 14, 2025
pulisher
Apr 12, 2025

3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance

Apr 12, 2025
pulisher
Apr 10, 2025

Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 08, 2025

Viking Therapeutics stock hits 52-week low at $20.26 - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Viking Therapeutics stock hits 52-week low at $20.26 By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Goldman Sachs Initiates Coverage of Viking Therapeutics (VKTX) with Neutral Recommendation - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4) - Quantisnow

Apr 08, 2025
pulisher
Apr 08, 2025

Goldman Sachs Initiates Coverage on Viking Therapeutics (VKTX) w - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

Viking Therapeutics stock rated Neutral at Goldman (VKTX) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Goldman initiated coverage on Viking Therapeutics with a new price target - Quantisnow

Apr 08, 2025
pulisher
Apr 08, 2025

Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Goldman Sachs sets Viking Therapeutics stock at Neutral By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 05, 2025

The Smartest Biotech Stocks to Buy With $50 - AOL.com

Apr 05, 2025
pulisher
Apr 03, 2025

When the Price of (VKTX) Talks, People Listen - news.stocktradersdaily.com

Apr 03, 2025
pulisher
Apr 03, 2025

Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow

Apr 03, 2025
pulisher
Apr 03, 2025

Viking therapeutics director Rouan buys $29,942 in stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Viking therapeutics director Rouan buys $29,942 in stock - Investing.com India

Apr 02, 2025

Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
Kapitalisierung:     |  Volumen (24h):